Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from BridgeBio Pharma ( (BBIO) ).
On February 12, 2026, BridgeBio reported positive topline results from its global Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia, showing a highly significant improvement in annualized height velocity over placebo at Week 52 and the highest absolute growth rates yet seen in a randomized achondroplasia study. The trial also met a key secondary endpoint on height Z‑score and, in children under eight, delivered the first statistically significant improvement in body proportionality versus placebo for any therapy in this condition.
Infigratinib was well tolerated, with no drug‑related discontinuations or serious adverse events and only mild, transient hyperphosphatemia, and no safety signals typically associated with FGFR1/2 inhibition or CNP analogues. On the back of these data, BridgeBio plans regulatory submissions for achondroplasia in the second half of 2026 and is accelerating Phase 3 development of infigratinib in hypochondroplasia, moves that could broaden treatment options and reinforce its position in the emerging market for targeted, oral therapies for skeletal dysplasias.
The most recent analyst rating on (BBIO) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.
Spark’s Take on BBIO Stock
According to Spark, TipRanks’ AI Analyst, BBIO is a Neutral.
The score is held back primarily by weak financial fundamentals (losses, negative equity, and soft free-cash-flow trend) despite strong revenue growth. Offsetting this, technicals are favorable with an uptrend across key moving averages, and the latest earnings call and recent corporate updates highlighted strong Attruby traction, multiple late-stage clinical wins, and solid liquidity, partially mitigating valuation concerns tied to unprofitability.
To see Spark’s full report on BBIO stock, click here.
More about BridgeBio Pharma
BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing medicines for genetic conditions, with a particular emphasis on skeletal dysplasias such as achondroplasia and hypochondroplasia. Its pipeline includes oral infigratinib, a targeted FGFR3 inhibitor that has received multiple regulatory designations for rare pediatric and orphan diseases, underscoring its strategic positioning in niche, high‑need genetic markets.
The company is advancing infigratinib across several age groups and related disorders, including an infant and toddler achondroplasia trial and Phase 3 development in hypochondroplasia. By prioritizing orally administered therapies that address underlying molecular drivers, BridgeBio is aiming to differentiate itself from existing injectable treatments and expand its role in the evolving market for growth‑modifying therapies.
Average Trading Volume: 2,466,583
Technical Sentiment Signal: Buy
Current Market Cap: $13.97B
Learn more about BBIO stock on TipRanks’ Stock Analysis page.